pharma · CDK Gene Mutation · Solid Tumor, Adult · KZIA
Kazia Therapeutics
KAZIA THERAPEUTICS LTD
Kazia Therapeutics is a pharma organization headquartered in Barangaroo, AU. It trades on NYSE under ticker KZIA. Primary therapeutic focus areas include CDK Gene Mutation, Solid Tumor, Adult, Brain and Central Nervous S
300 Barangaroo Ave, L24, Barangaroo, New South Wales 2000, AU HQ
2016 Founded
15 Employees
Public company Type
KZIA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 300 Barangaroo Ave, L24, Barangaroo, New South Wales 2000, AU
- Founded
- 2016
- Employees
- 15
- Programs
- 13
- Drugs
- 9
- Patents
- 1
GDC-0084
Phase 1 · small molecule · Brain and Central Nervous System Tumors
GDC-0084 for Brain and Central Nervous System Tumors is a Phase 1 program (small_molecule) at KAZIA THERAPEUTICS LTD with 1 ClinicalTrials.gov record(s).
Internal code SJPI3K
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- KAZIA THERAPEUTICS LTD
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Brain and Central Nervous System Tumors
- Status
- completed
- Trials
- 1